WAVE Life Sciences Q2 2025 Earnings Report

WAVE Life Sciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.28
• Beat/Miss: N/A
• One Year Ago EPS: N/A

WAVE Life Sciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

WAVE Life Sciences Announcement Details

• Quarter: Q2 2025
• Date: 8/14/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, August 7, 2025
• Conference Call Time: 8:30AM ET

WAVE Life Sciences (NASDAQ:WVE) Corporation is a clinical-stage biotechnology company dedicated to the development of stereopure oligonucleotide therapies that address underlying genetic drivers of disease. The company leverages a proprietary platform to design and manufacture single-isomer oligonucleotides with enhanced potency, specificity and durability. Its research and development efforts are focused on a range of neuromuscular, neurodegenerative and metabolic disorders with significant unmet medical need.

WAVE’s Precision Oligo™ chemistry platform enables the production of oligonucleotides with defined three-dimensional structures, which the company believes can improve tissue distribution and therapeutic indices relative to conventional oligos. Key programs in clinical development include treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), with additional preclinical efforts targeting Huntington’s disease, acute hepatic porphyria and other rare genetic conditions. WAVE has also entered strategic collaborations with major biopharmaceutical partners to accelerate discovery and development of oligonucleotide-based oncology and metabolic disease programs.

Founded in 2014 and headquartered in Cambridge, Massachusetts, WAVE Life Sciences operates complementary research facilities in the United Kingdom and maintains partnerships in Asia and Europe to support global development. The company’s leadership team combines expertise in oligonucleotide chemistry, clinical development and manufacturing scale-up, positioning WAVE to advance its pipeline through late-stage trials and regulatory filings. With a mission to translate cutting-edge oligonucleotide science into transformative therapies, WAVE continues to expand its platform capabilities and foster collaborations that broaden its therapeutic reach.